Detection of RAS mutations in circulating tumor cells: applications in colorectal cancer and prospects.
The somatic mutations in the RAS genes (KRAS and NRAS) are widely associated with non-response to immunotherapies targeting the epidermal growth factor receptor in metastatic colorectal cancer. The detection of these mutations is carried out from tissue biopsies and become mandatory to prescribe these treatments. Nethertheless, this analysis is not possible in about 25% of cases and the development of alternative methods is therefore required. Among them, the search for mutations directly in the blood of patients are promising approaches. Circulating tumor cells (CTCs) represent a particularly relevant direct target. These cells, some of them have inducing-metastasis capabilities, have been able to detach themselves from the primary tumor, then migrate and finally enter into the bloodstream. In this sense, they are particularly resistant to physical-chemical and immunological constraints used by the organism to prevent their dissemination. Consequently, they represent a particularly valuable source of information on the most aggressive tumor cells. As a corollary, these cells are very rare requiring particularly highly performant technologies to be detected. In this presentation, we focus mainly on the molecular methods used to detect these mutated RAS cells by analyzing the performance of a solution based on a filtration device followed by detection with digital PCR. Finally, we will discuss the biological significance of these cells before highlighting prospects in colorectal cancer but also in other cancers.